Kestra Medical Technologies
Kirkland, Washington, United States · Biotechnology, Health Care, Medical · 275 employees
Kestra Medical Technologies, Inc. is a privately held wearable medical device and digital healthcare company that protects cardiac patients with diagnostic monitoring and therapeutic technologies. Kestra was founded in 2014 by Bain Capital private equity and leaders from the external (AED) and internal (ICD) defibrillation industries.
Funding history
- Series series a — $25.0M — Apr 2026
- Series public offering — $158.7M — Dec 2025
- Funding Round — $196.0M — Jul 2024
Recent signals
- Apr 06, 2026: Raised $25.0M in Series series a
- Jan 13, 2026: Kestra Medical Technologies partners with Biobeat to enhance blood pressure monitoring for cardiac recovery.
- Dec 04, 2025: Raised $158.7M in Series public offering
- Dec 02, 2025: SEC 8-K (1.01): On December 2, 2025, Kestra Medical Technologies, Ltd. entered into an Underwriting Agreement with BofA Securities, Inc., Piper Sandler & Co., J.P. Morgan Securities LLC, and Goldman Sachs & Co. LLC for a public offering of 6,900,000 common shares at a purchase price of $23.00 per share. The Offering included an additional 900,000 shares from the Underwriters' option to purchase more at the same price, which is typical in such financial agreements. This capital raising activity indicates a strategy to strengthen the company's financial position and expand its market presence, with the total proceeds expected to significantly support future investments and operational initiatives.
- Oct 07, 2025: Kestra Medical Technologies Appoints Timothy Moran as Chief Business Officer
- Jul 24, 2024: Raised $196.0M
See plans & pricing → Track Kestra Medical Technologies’s funding, hiring, and signals — with verified contacts — on Fundz.